

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

NCT07375225

Status RECRUITING
Sponsor Federico II University
Enrollment 1,500 participants

Key Eligibility Criteria

Inclusion (1)

- Patients under alirocumab 300mg treatment.

Exclusion (2)

- Age < 18 years or > 80 years;
- Patients who refuse to participate and to sign informed consent.

Locations (1 total)

Federico II University of Naples, Department of Advanced Biomedical Sciences, Naples, Napoli, Italy